AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (February 15, 2005). doi:10.1152/ajpendo.00583.2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/1/E46    most recent
00583.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiCostanzo, C. A.
Right arrow Articles by Cherrington, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DiCostanzo, C. A.
Right arrow Articles by Cherrington, A. D.
Submitted on December 10, 2004
Accepted on February 9, 2005

Simulated First-Phase Insulin Release Using Humulin or an Insulin Analogue (HIM2) is Associated with Prolonged Improvement in Post-Prandial Glycemia

Catherine A. DiCostanzo1*, Mary Courtney Moore2, Margaret Lautz2, Melanie Scott2, Ben Farmer2, Carrie A. Everett2, J. Gordon Still2, Alan Higgins2, and Alan D. Cherrington2

1 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA; Diabetes Research and Training Center, Vanderbilt University, Nashville, TN, USA
2 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA

* To whom correspondence should be addressed. E-mail: catherine.dicostanzo{at}vanderbilt.edu.

We examined the extent to which priming the liver with a pulse of humulin or an insulin analogue (HIM2) reduces postprandial hyperglycemia. Somatostatin (0.5 µg/kg/min) was given with basal intraportal insulin and glucagon for 4.5h into 3 groups of 42h fasted conscious dogs. From 0-5min, group one (BI, n=6) received saline, group two (HI, n=6) received a Humulin pulse (10 mU/kg/min), and group three (HIM2, n=6) received a HIM2 pulse (10 mU/kg/min). Duodenal glucose was infused (5.0 mg/kg/min) from 15-270min. Arterial insulin (µU/ml) in BI remained basal (6±1), while it peaked at 52±15 (HI) and 164±44 (HIM2) and returned to baseline by 30 and 60 min, respectively. Arterial plasma glucose (mg/dl) plateaued at 265±20, 214±15 and 193±14 in BI, HI, and HIM2. Glucose absorption was similar in all groups. Significant net hepatic glucose uptake occurred at 85, 55, and 25 min in BI, HI, and HIM2, respectively. Nonhepatic glucose clearance (ml/kg/min) at 270min differed among groups (BI, HI, HIM2)0.62±0.11, 0.76±0.26, and 1.61±0.29 (P<0.05). A brief (5min) insulin pulse improved post-prandial glycemia, stimulating hepatic glucose uptake and prolonging enhancement of non-hepatic glucose clearance. HIM2 was more effective than Humulin perhaps because its lowered clearance caused higher levels at the liver and periphery and its biologic activity was not reduced proportionally to its decreased clearance.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.